Navigation Links
Better treatment for brain cancer revealed by new molecular insights
Date:7/9/2012

Nearly a third of adults with the most common type of brain cancer develop recurrent, invasive tumors after being treated with a drug called bevacizumab. The molecular underpinnings behind these detrimental effects have now been published by Cell Press in the July issue of Cancer Cell. The findings reveal a new treatment strategy that could reduce tumor invasiveness and improve survival in these drug-resistant patients.

"Understanding how and why these tumors adopt this invasive behavior is critical to being able to prevent this recurrence pattern and maximizing the benefits of bevacizumab," says study author Kan Lu of the University of California, San Francisco (UCSF).

Glioblastoma multiforme (GBM) is the most aggressive type of tumor originating in the brain. GBM tumors express high levels of vascular endothelial growth factor (VEGF), a protein that promotes the growth of new blood vessels that provide nutrients that allow tumors to expand. In 2009, the Food and Drug Administration approved bevacizumab, a VEGF inhibitor, for GBM patients who don't respond to first-line therapies. Although the drug is initially effective, up to 30% of patients develop tumors that infiltrate deep into the brain, making surgery and treatment difficult.

To study how bevacizumab can lead to adverse effects, senior study author Gabriele Bergers of UCSF and her collaborators focused on hepatocyte growth factor (HGF), a protein that controls the growth and movement of cells, because they previously found a link between VEGF and HGF in GBM cells. In the new study, they found that VEGF inhibits the migration of GBM cells by decreasing HGF signaling through its receptor MET. Moreover, tumors were much less invasiveand survival improvedin mice with GBM tumors lacking both VEGF and MET rather than just VEGF alone. The results suggest that MET plays a critical role in GBM invasion when VEGF is blocked.

"These findings provide a rationale for therapeutically combining VEGF and MET inhibition so that patients can benefit from bevacizumab without developing more invasive tumors," Lu says. Because the VEGF and HGF/MET signaling pathways are active in a variety of tumors, this combined treatment strategy may also be applied to other types of cancer.


'/>"/>

Contact: Elisabeth (Lisa) Lyons
elyons@cell.com
617-386-2121
Cell Press
Source:Eurekalert

Related medicine news :

1. A better tool to diagnose tuberculosis
2. Job injuries among youth prompt calls for better safety standards
3. Students focus on creating a better cervical collar
4. Out-of-hand tree nut consumption associated with better diet quality in children and adults
5. Kidney cancer patients do better when whole kidney is not removed, U-M study shows
6. Kidney Cancer Patients Fare Better With Tumor Removal Only
7. New Psoriasis Drugs Not Much Better Than Standard Therapy, Study Finds
8. Hispanics Seem to Have Better Odds of Lung Cancer Survival
9. Which ads are winners? Your brain knows better than you do
10. Better health in adulthood starts with early prevention in childhood
11. MR enterography is as good or better than standard imaging exams for pediatric Crohns patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... ... May 24, 2017 , ... Dr. Alan I. Benvenisty, ... in New York City. He is known for his distinguished expertise and experience in ... Dr. Benvenisty holds sub-specialty training in treating renovascular disease and aortic aneurysm . ...
(Date:5/24/2017)... ... May 24, 2017 , ... ... in Bayside, NY, who have now spent 10 years as clinical instructors for ... University (NYU) College of Dentistry. Through the program, private practitioners receive cutting-edge clinical ...
(Date:5/24/2017)... ... May 24, 2017 , ... STATEMENT OPPOSING PRESIDENT ... opposed to Donald Trump’s budget, “A New Foundation for American Greatness—President's Budget FY ... the poor, marginalizes underserved populations, undermines productivity, and destroys the social safety net ...
(Date:5/24/2017)... ... May 24, 2017 , ... ... female reproductive tract in which the endometrial lining of the uterus spreads ... and pain. Patients experiencing painful intercourse, painful periods, pelvic pain, or irregular ...
(Date:5/24/2017)... California (PRWEB) , ... May 24, 2017 , ... If you are thinking of a ... are interested in business architecture, October is the perfect time to visit. , Business Architecture ... an à la carte offering for individuals, as a 4-½ day package for individuals, and ...
Breaking Medicine News(10 mins):
(Date:5/9/2017)... , May 9, 2017 Zimmer Biomet Holdings, ... musculoskeletal healthcare, today announced it has earned a spot ... 2017" list. The Company was ranked among 500 U.S. ... Employers and Healthcare Equipment and Services. The ... on an anonymous, independent survey of over 30,000 employees ...
(Date:5/8/2017)... 2017 MACRA replaces the outdated sustainable ... service reimbursement. Black Book Research crowdsource-surveyed 8,845 physician practices ... The Market for MIPS Compliance Technology is Booming ... with 3 or more clinicians seek to buy Merit-Based ... the magnitude of the changes, the hunt is on ...
(Date:5/6/2017)... N.Y. , May 5, 2017  Hill-Rom Holdings, ... will add approximately 100,000 square feet to its Welch ... September 2016 its commitment to bring more than 100 ... , where Welch Allyn has maintained a significant presence ... help accommodate these new positions, a large portion of ...
Breaking Medicine Technology: